Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
4(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
3
38%
Ph phase_2
1
13%
Ph phase_1
1
13%
Ph phase_3
3
38%

Phase Distribution

1

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
3(37.5%)
Phase 4Post-market surveillance
3(37.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(4)
Completed(4)

Detailed Status

Recruiting4
Completed4

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 21 (12.5%)
Phase 33 (37.5%)
Phase 43 (37.5%)

Trials by Status

recruiting450%
completed450%

Recent Activity

4 active trials
Showing 5 of 8
completedphase_3

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

NCT06126783
completedphase_3

A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy

NCT06269393
recruitingphase_3

A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease

NCT07113262
recruitingphase_4

Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.

NCT07152366
recruitingphase_4

The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.

NCT07152340
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06126783Phase 3

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

Completed
NCT06269393Phase 3

A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy

Completed
NCT07113262Phase 3

A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease

Recruiting
NCT07152366Phase 4

Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.

Recruiting
NCT07152340Phase 4

The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.

Recruiting
NCT07152392Phase 4

Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO

Recruiting
NCT05795621Phase 2

A Study of IBI311 in Subjects With Active Thyroid Eye Disease

Completed
NCT05480579Phase 1

A Study of IBI311 in Healthy Volunteers

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8